Carcinoma, Non-Small-Cell Lung

Showing NaN - NaN of 59

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

NSCLC, Tumor Metastasis Trial in Worldwide (LY3537982, Pembrolizumab, Placebo)

Not yet recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Neoplasm Metastasis
  • Tucson, Arizona
  • +217 more
Nov 1, 2023

NSCLC Trial in Korea, Republic of, Malaysia, United States (Cetrelimab, Amivantamab)

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Fairfax, Virginia
  • +3 more
Jun 16, 2023

NSCLC Trial in Worldwide (Lazertinib, Amivantamab, Carboplatin)

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Los Angeles, California
  • +83 more
Jan 31, 2023

NSCLC Trial in Worldwide (Amivantamab, Pemetrexed, Carboplatin)

Active, not recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Duarte, California
  • +228 more
Jan 31, 2023

NSCLC Trial in Japan, Korea, Republic of, Singapore (capmatinib, pemetrexed, cisplatin)

Terminated
  • Carcinoma, Non-Small-Cell Lung
  • Kashiwa, Chiba, Japan
  • +3 more
Jan 31, 2023

NSCLC Trial in Worldwide (TAK-788)

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Birmingham, Alabama
  • +56 more
Jan 23, 2023

NSCLC Trial in Worldwide (Alectnib, Cisplatin, Vinorelbine)

Active, not recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Chicago, Illinois
  • +140 more
Jan 20, 2023

KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small Cell Lung, NSCLC Trial (JDQ443, trametinib, Ribociclib)

Recruiting
  • KRAS G12C Mutant Solid Tumors
  • +10 more
  • Boston, Massachusetts
  • +5 more
Jan 11, 2023

NSCLC Trial in Worldwide (Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody, Docetaxel)

Completed
  • Carcinoma, Non-Small-Cell Lung
  • Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody
  • Docetaxel
  • Beijing, China
  • +37 more
Jan 9, 2023

NSCLC Trial in Worldwide (INC280 (capmatinib))

Active, not recruiting
  • Carcinoma, Non-Small-Cell Lung
  • INC280 (capmatinib)
  • Long Beach, California
  • +95 more
Dec 29, 2022

NSCLC Trial in Worldwide (Selpercatinib, Placebo)

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Santa Monica, California
  • +206 more
Dec 27, 2022

NSCLC Trial in Worldwide (Durvalumab, Placebo, Osimertinib (single-arm, open-label))

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Tuscaloosa, Alabama
  • +260 more
Dec 16, 2022

RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer, RET-altered Papillary Thyroid Cancer Trial in Worldwide

Active, not recruiting
  • RET-altered Non Small Cell Lung Cancer
  • +39 more
  • pralsetinib (BLU-667)
  • Phoenix, Arizona
  • +65 more
Nov 10, 2022

Lung Tumors, NSCLC, Respiratory Tract Tumors Trial in Worldwide (BLU-945, osimertinib)

Recruiting
  • Lung Neoplasms
  • +23 more
  • La Jolla, California
  • +35 more
Oct 6, 2022

Tumors, NSCLC, Pancreatic Tumors Trial in Worldwide (V941, Pembrolizumab)

Completed
  • Neoplasms
  • +3 more
  • V941
  • Pembrolizumab
  • Gilbert, Arizona
  • +25 more
Sep 5, 2022

Korea Osimertinib Real World Evidence Study to Assess Safety and

Recruiting
  • Carcinoma, Non-Small-Cell Lung
    • Busan, Korea, Republic of
    • +10 more
    Aug 18, 2022

    Lung Tumors, NSCLC Trial in Worldwide (biological, drug, radiation)

    Recruiting
    • Lung Neoplasms
    • Carcinoma, Non-Small-Cell Lung
    • Pembrolizumab
    • +9 more
    • Mobile, Alabama
    • +194 more
    Aug 18, 2022

    NSCLC Trial in Worldwide (Amivantamab, Osimertinib, Lazertinib)

    Active, not recruiting
    • Carcinoma, Non-Small-Cell Lung
    • Goodyear, Arizona
    • +266 more
    Aug 17, 2022

    NSCLC Trial in Worldwide (Lazertinib, Amivantamab, Pemetrexed)

    Recruiting
    • Carcinoma, Non-Small-Cell Lung
    • Phoenix, Arizona
    • +303 more
    Aug 17, 2022

    Uterine Tumors, Uterine Cervical Tumors, Biliary Tract Tumors Trial in Worldwide (tucatinib, trastuzumab, fulvestrant)

    Recruiting
    • Uterine Neoplasms
    • +5 more
    • Goodyear, Arizona
    • +63 more
    Aug 15, 2022

    NSCLC Trial in Worldwide (Capmatinib, Amivantamab)

    Not yet recruiting
    • Carcinoma, Non-Small-Cell Lung
    • Orange, California
    • +40 more
    Aug 3, 2022

    NSCLC Trial in Worldwide (Durvalumab + SoC chemo, Placebo + SoC chemo)

    Active, not recruiting
    • Carcinoma, Non-Small-Cell Lung
    • Durvalumab + SoC chemotherapy
    • Placebo + SoC chemotherapy
    • Birmingham, Alabama
    • +147 more
    Aug 1, 2022

    KRAS G12C Mutant Solid Tumors, NSCLC, Carcinoma, Colorectal Trial in Worldwide (JDQ443, TNO155, tislelizumab)

    Recruiting
    • KRAS G12C Mutant Solid Tumors
    • +9 more
    • Atlanta, Georgia
    • +31 more
    Jul 7, 2022

    NSCLC, Immune Checkpoint Inhibitors Trial in Seoul (F-18 FDG PET/CT)

    Recruiting
    • Carcinoma, Non-Small-Cell Lung
    • Immune Checkpoint Inhibitors
    • F-18 FDG PET/CT
    • Seoul, Korea, Republic of
      Samsung Medical Center
    Jun 15, 2022

    NSCLC Trial in Worldwide (Lorlatinib, Crizotinib)

    Active, not recruiting
    • Carcinoma, Non-Small-Cell Lung
    • Altamonte Springs, Florida
    • +164 more
    May 27, 2022